This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Bruker Rides on Nano and MALDI Launches Despite Margin Debacle
by Zacks Equity Research
Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.
Abbott's Data From Interim Clinical Study of ID NOW Positive
by Zacks Equity Research
Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.
Veeva Develops 2 Applications on Veeva Clinical Network (Revised)
by Zacks Equity Research
This should boost Veeva's (VEEV) portfolio of cloud-based offerings for the life sciences industry.
Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.
Ecolab Introduces New Automated Precision Dispensing System
by Zacks Equity Research
Ecolab's (ECL) newly launched Precision Dispensing System for Membranes can drive productivity and boost worker safety.
Pacific Biosciences Unveils Sequel IIe for HiFi Sequencing
by Zacks Equity Research
Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology.
Masimo Unveils New Wearable Wireless Continuous Thermometer
by Zacks Equity Research
Masimo's (MASI) wearable wireless continuous thermometer offers consumers hassle-free continuous body temperature measurements, thereby eliminating the need for manual measurements.
Ecolab Disinfectant Gets EPA Nod for Use Against SARS-CoV-2
by Zacks Equity Research
Ecolab's (ECL) Peroxide Multi Surface Cleaner and Disinfectant is the first EPA-registered disinfectant proven to be effective at killing the SARS-CoV-2 virus.
Ecolab Launches Sanitizer to Prevent Food-Borne Illness
by Zacks Equity Research
Ecolab's (ECL) Sink & Surface Cleaner Sanitizer is the first EPA-registered product for use against norovirus and SARS-CoV-2.
Here's Why You Should Retain Fresenius Medical Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.
BD Gets 510(k) Clearance for Its FACSLyric Flow Cytometer
by Zacks Equity Research
BD (BDX) gets 510(k) clearance from the FDA for its new integrated system that helps clinical laboratories to fully automate the sample to answer process and boost their efficiency.
Boston Scientific, Farapulse Sign Deal for Treatment of AF
by Zacks Equity Research
Boston Scientific (BSX) aims to provide a comprehensive portfolio of electrophysiology products and services via the latest investment agreement.
Boston Scientific Launches DBS System in Europe Post Approval
by Zacks Equity Research
Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.
Here's Why You Should Hold on to Medtronic Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on robust segmental growth and strong ventilators sales.
Boston Scientific's Eluvia Gets CMS' Additional Reimbursement
by Zacks Equity Research
Boston Scientific (BSX) gains CMS' NTAP designation for its Eluvia stent system, thus providing additional reimbursement to Medicare beneficiaries suffering from PAD.
Boston Scientific (BSX) Up 4.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific's Voraxaze's MAA Accepted by EMA for Review
by Zacks Equity Research
Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.
Boston Scientific (BSX) Q2 Earnings Top, Margins Decline
by Zacks Equity Research
This time too Boston Scientific (BSX) refrains from providing any update on the full-year guidance.
Boston Scientific (BSX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 300.00% and 22.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Deferred Procedures to Mar Boston Scientific (BSX) Q2 Earnings
by Zacks Equity Research
With lockdowns continuing through all three months of the second quarter, Boston Scientific (BSX) is expected to have faced a more dreadful time.
Earnings Preview: Boston Scientific (BSX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic's LINQ II ICM Gets Multiple Regulatory Approvals
by Zacks Equity Research
Medtronic's (MDT) FDA and CE Mark-approved LINQ II ICM enables physicians to optimize device settings via remote programming, without requiring patients' in-office visits.
Boston Scientific's (BSX) ICM System Receives FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.